Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Former biotech CEO sued over COVID vaccine alleged insider trading - 2Survey: Canteen Cups With Great Warm Protection Impact
- 3Artemis II crew cleared to depart Earth orbit, head for moon
- 4Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- 5James Webb Space telescope spots 'big red dot' in the ancient universe: A ravenous supermassive black hole named 'BiRD'
- Artemis II astronauts find hidden Easter eggs as they close in on the moon
- Watch the Geminid meteor shower peak tonight from the comfort of home with this free livestream
- What you need to know about desalination, a growing source of drinking water
- Flu season is ramping up, and some experts are "pretty worried"
- Oil rises above $115 and Asia stocks slide as Iran war escalates
- New movies to watch this weekend: See 'Predator: Badlands' in theaters, rent 'Black Phone 2,' stream Guillermo del Toro's 'Frankenstein' on Netflix
- See tonight’s solar storm unfold across the world
- Russia downs 16 drones heading for Moscow, mayor says
- Get away from the Tedious Drudgery: Go into Business Today!
